Wells Fargo
CTMX icon

Wells Fargo’s CytomX Therapeutics CTMX Stock Holding History

Wells Fargo’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
163,183
+156,588
+2,374% +$598K ﹤0.01% 4477
2026
Q1 		$31K Sell
6,595
-10
-0.2% -$51 ﹤0.01% 5621
2025
Q4 		$28.1K Buy
6,605
+3,000
+83% +$11.4K ﹤0.01% 5699
2025
Q3 		$11.5K Buy
+3,605
New +$8.12K ﹤0.01% 5916
2024
Q2 		– Sell
-524
Closed -$1.14K – 7016
2024
Q1 		$1.14K Buy
524
+9
+2% +$17 ﹤0.01% 6120
2023
Q4 		$798 Buy
515
+28
+6% +$37 ﹤0.01% 6282
2023
Q3 		$628 Buy
487
+9
+2% +$14 ﹤0.01% 6315
2023
Q2 		$822 Buy
478
+21
+5% +$35 ﹤0.01% 6370
2023
Q1 		$690 Buy
457
+7
+2% +$16 ﹤0.01% 6478
2022
Q4 		$720 Buy
450
+12
+3% +$18 ﹤0.01% 6283
2022
Q3 		$1K Buy
438
+31
+8% +$48 ﹤0.01% 6309
2022
Q2 		$1K Sell
407
-84,824
-100% -$162K ﹤0.01% 6489
2022
Q1 		$228K Sell
85,231
-19,393
-19% -$74.5K ﹤0.01% 4904
2021
Q4 		$452K Buy
104,624
+14,055
+16% +$82.3K ﹤0.01% 4740
2021
Q3 		$460K Buy
90,569
+37,591
+71% +$201K ﹤0.01% 4710
2021
Q2 		$335K Sell
52,978
-91,777
-63% -$715K ﹤0.01% 4812
2021
Q1 		$1.12M Buy
144,755
+44,940
+45% +$356K ﹤0.01% 4163
2020
Q4 		$654K Sell
99,815
-7,496
-7% -$53.6K ﹤0.01% 4331
2020
Q3 		$714K Buy
107,311
+6,702
+7% +$49.7K ﹤0.01% 4101
2020
Q2 		$838K Buy
100,609
+73,726
+274% +$685K ﹤0.01% 3949
2020
Q1 		$206K Buy
26,883
+2,297
+9% +$16K ﹤0.01% 4665
2019
Q4 		$204K Buy
24,586
+22
+0.1% +$148 ﹤0.01% 4944
2019
Q3 		$181K Buy
24,564
+1,408
+6% +$13.9K ﹤0.01% 5012
2019
Q2 		$260K Sell
23,156
-56,880
-71% -$596K ﹤0.01% 4819
2019
Q1 		$861K Sell
80,036
-28,189
-26% -$417K ﹤0.01% 3990
2018
Q4 		$1.63M Buy
108,225
+13,240
+14% +$196K ﹤0.01% 3443
2018
Q3 		$1.76M Buy
94,985
+4,020
+4% +$91.6K ﹤0.01% 3519
2018
Q2 		$2.08M Buy
90,965
+31,364
+53% +$801K ﹤0.01% 3428
2018
Q1 		$1.7M Sell
59,601
-82,353
-58% -$2.35M ﹤0.01% 3499
2017
Q4 		$3M Buy
141,954
+81,215
+134% +$1.68M ﹤0.01% 3041
2017
Q3 		$1.1M Buy
60,739
+19,506
+47% +$304K ﹤0.01% 3770
2017
Q2 		$639K Buy
41,233
+18,809
+84% +$284K ﹤0.01% 4053
2017
Q1 		$387K Buy
22,424
+7,747
+53% +$102K ﹤0.01% 4416
2016
Q4 		$161K Buy
14,677
+6,869
+88% +$83.2K ﹤0.01% 4882
2016
Q3 		$122K Buy
7,808
+5,600
+254% +$67.8K ﹤0.01% 4794
2016
Q2 		$23K Sell
2,208
-155
-7% -$1.77K ﹤0.01% 5459
2016
Q1 		$31K Buy
2,363
+128
+6% +$1.78K ﹤0.01% 5388
2015
Q4 		$47K Buy
+2,235
New +$35.4K ﹤0.01% 5305

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Wells Fargo's CTMX Position: Q2 2026 in Review

Wells Fargo increased its CytomX Therapeutics (CTMX) stake by 2,374% in Q2 2026, buying an estimated $598K and bringing the position to 163,183 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #4477.

Wells Fargo first reported a position in CTMX in Q4 2015 and has held it in 38 quarters since. The position peaked at $3M in Q4 2017. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Wells Fargo held 163,183 shares of CytomX Therapeutics worth $612K as of Q2 2026.
  • Wells Fargo bought 156,588 CytomX Therapeutics shares in Q2 2026, an estimated $598K.
  • CytomX Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4477 holding.
  • Wells Fargo first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 38 quarters since.
  • Wells Fargo's CytomX Therapeutics position peaked at $3M in Q4 2017.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.